Safety data sheet. GHS / OSHA HCS 2012 format, 16 sections. Issued by Epic Peptides Lab for the catalogue items listed in Section 1.

Epic Peptides Lab

Safety data sheet · capsules

Epic Peptides Lab · USA

Document number: PL-SDS-111
Revision: 1.0 · 2026-10-03

MK-677

capsules

1Identification

Product Identifier

MK-677

Document Number

PL-SDS-111

Catalogue Items Covered

Id
8615
Name
MK-677 (Ibutamoren) (10mg/capsule) 60 Capsules
Sku
PL-MK677-10MG-CAP

Recommended Use

Laboratory research use by trained personnel.

Restrictions On Use

Not for human or veterinary use.

Supplier / Distributor

Epic Peptides Lab, USA

Telephone

+1 (787) 468-5291

info@epicpeptideslab.com

2Hazard(s) identification

Classification: Not classified as hazardous under OSHA HCS 2012 (29 CFR 1910.1200) or UN GHS, on the basis of the supplier safety data sheets consulted.
Label Elements: No data available.
Signal Word: No data available.
Other Hazards: No data available.

3Composition / information on ingredients

Description

Hard gelatin capsules containing the active substance blended with microcrystalline cellulose, packed in a sealed bottle.

Composition

Name
MK-677
Full
Ibutamoren (MK-677), ghrelin receptor agonist (mesylate as commonly supplied)
Cas
159752-10-0
Formula
C27H36N4O5S
Conc
2.5% w/w of capsule contents (nominal)
Qty
10 mg per capsule
Hazards
- Acute toxicity, oral — Category 3 — H301
Name
Microcrystalline cellulose
Full
Microcrystalline cellulose (capsule filler)
Cas
9004-34-6
Formula
(C6H10O5)n
Conc
balance of capsule contents
Name
Gelatin
Full
Gelatin (capsule shell)
Cas
9000-70-8
Conc
capsule shell

4First-aid measures

First Aid Measures

Inhalation: Move the person to fresh air and keep comfortable for breathing. If breathing is difficult or symptoms persist, call a POISON CENTER or doctor.
Skin: Take off contaminated clothing. Wash the skin with plenty of soap and water. If irritation or a rash develops, get medical advice.
Eyes: Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do; continue rinsing. If eye irritation persists, get medical advice.
Ingestion: Rinse mouth. Do not induce vomiting. Call a POISON CENTER or doctor if you feel unwell.

Most Important Symptoms And Effects

No specific symptoms are known. Pharmacologically active material: systemic effects consistent with its mechanism of action are possible after accidental injection, ingestion or absorption.

Likely Routes Of Exposure

Ingestion; inhalation of dust and skin/eye contact if capsules are opened.

5Fire-fighting measures

Fire Fighting Information: Combustible organic solid; capsule contents may form combustible dust if dispersed in bulk.

6Accidental release measures

Spill And Clean Up Procedures: Collect intact capsules. Dampen any spilled powder with water, wipe up with absorbent material and place in a sealed container for disposal.

7Handling and storage

Safe Handling: Do not open or crush capsules unless required for an experiment; if capsule contents are handled as a powder, avoid generating dust and weigh inside a ventilated enclosure. Wash hands after handling.
Safe Storage: Store at room temperature (15–25 °C) in the tightly closed original container, dry and protected from light.
Storage Temperature: 15–25 °C, dry, protected from light
Incompatible Materials: Strong oxidizing agents (Cayman)

8Exposure controls / personal protection

Occupational Exposure Limits: Microcrystalline cellulose: OSHA PEL 15 mg/m³ (total dust), 5 mg/m³ (respirable fraction); ACGIH TLV 10 mg/m³ (as cellulose).

No occupational exposure limits have been established for the active ingredient(s).
Exposure Controls And PPE: No data available.

9Physical and chemical properties

Physical State

Solid

Appearance

Hard gelatin capsules containing a white to off-white powder

Properties

Odor: Characteristic (Cayman)
Ph: Not applicable (solid)
Melting: Undetermined (Cayman); no data (ChemicalBook)
Boiling: No data available
Flash: Not applicable (non-flammable solid); combustible organic material
Vapour: Negligible (solid)
Density: No data available (bulk density of lyophilized cake is low)
Solubility: Mesylate: DMF 25 mg/mL; DMSO 25 mg/mL; ethanol 10 mg/mL; PBS (pH 7.2) 10 mg/mL (Cayman); water 5 mg/mL clear (ChemicalBook); DMSO 252.5 mg/mL (TargetMol). Free base: water soluble (Cayman 44475)
Logp: No data available
Decomp: No data available; peptides decompose above about 200 °C
Other: Mesylate salt C27H36N4O5S . CH4O3S, MW 624.8, CAS 159752-10-0; free base C27H36N4O5S, MW 528.7, CAS 159634-47-6, density 1.32 g/cm3 (Cayman). Not flammable.

10Stability and reactivity

Stability And Reactivity

Reactivity: No dangerous reactions known
Incompatible: Strong oxidizing agents (Cayman)
Decomposition: Carbon dioxide, carbon monoxide, nitrogen oxides, sulfur oxides (Cayman)
Conditions To Avoid: Heat, moisture; store at -20 C (powder stable 3 years per TargetMol)

Conditions To Avoid

Heat, moisture; store at -20 C (powder stable 3 years per TargetMol)

Incompatible Materials

No data available.

11Toxicological information

Toxicological Information: Acute toxicity, oral
Cayman 18003 (mesylate): oral TDLo 1 mg/kg (dog) - used by Cayman as basis for Category 1; Cayman 44475 (free base): oral LD50 100 mg/kg (species not stated) - Category 3; ChemicalBook: no data available. Bimeda-type ATE not available.

Acute toxicity, dermal
No data available

Acute toxicity, inhalation
No data available

Skin corrosion/irritation
No irritant effect (Cayman)

Serious eye damage/irritation
No irritating effect (Cayman)

Respiratory or skin sensitisation
No sensitizing effects known (Cayman)

Germ cell mutagenicity
No data available

Carcinogenicity
Not listed by IARC, NTP or OSHA

Reproductive toxicity
No data available (GH secretagogue; see notes)

STOT, single exposure
No data available

STOT, repeated exposure
Subcutaneous TDLo 300 mg/kg (rat) (Cayman 18003); clinical trials: increased appetite, edema, insulin resistance/raised fasting glucose, congestive heart failure signal in elderly hip-fracture trial

Aspiration hazard
No data available
Routes Of Exposure: Ingestion; inhalation of dust and skin/eye contact if capsules are opened.
Symptoms: No specific symptoms are known. Pharmacologically active material: systemic effects consistent with its mechanism of action are possible after accidental injection, ingestion or absorption.

12Ecological information

Ecological Information: No ecotoxicity data available. Cayman water hazard class 1 (self-assessment): slightly hazardous for water.

13Disposal considerations

Disposal Guidance: No data available.

14Transport information

Transport Classification

Note: Not regulated as a dangerous good for transport by road (DOT 49 CFR), air (IATA/ICAO) or sea (IMDG). Not a marine pollutant. Ship refrigerated or frozen as required by Section 7; the coolant (dry ice, UN 1845) is regulated when used.

15Regulatory information

Regulatory Information

Tsca: Not listed (Cayman, both salt and free base)
Carcinogen Listings: Not listed by IARC, NTP, OSHA, EPA, NIOSH
Dea: Not a federally controlled substance
Other: WADA Prohibited List S2.2.3 - growth hormone secretagogues (ibutamoren/MK-677 named) prohibited (remark only). Unapproved investigational drug; FDA has warned against its sale in supplements. Reported on FDA's 503A bulk drug substances 'Category 2' list - verify current list before citing.

Carcinogen Listings

No data available.

16Other information

Revision: October 3, 2026
Sources Consulted: Cayman Chemical

ChemicalBook MSDS

TargetMol product page

Spectrum Chemical

Sigachi Industries

Parchem

Fisher Scientific / Acros Organics

Electron Microscopy Sciences
Confidence: medium
Additional Information: Ghrelin receptor agonist (growth hormone secretagogue). WADA Prohibited List class S2.

Back to SDS list